| Year |
Citation |
Score |
| 2021 |
Wood ME, Liu H, Storrick E, Zahrieh D, Le-Petross HC, Jung SH, Zekan P, Kemeny MM, Charlamb JR, Wang LX, Unzeitig GW, Johnson CS, Garber JE, Marshall JR, Bedrosian I. The influence of vitamin D on mammographic density: results from CALGB 70806 (Alliance) a randomized clinical trial. Cancer Prevention Research (Philadelphia, Pa.). PMID 33849913 DOI: 10.1158/1940-6207.CAPR-20-0581 |
0.32 |
|
| 2020 |
Shaurova T, Dy GK, Battaglia S, Hutson A, Zhang L, Zhang Y, Lovly CM, Seshadri M, Goodrich DW, Johnson CS, Hershberger PA. Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. Cancers. 12. PMID 32183160 DOI: 10.3390/Cancers12030675 |
0.43 |
|
| 2019 |
Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle (Georgetown, Tex.). 1-12. PMID 31318640 DOI: 10.1080/15384101.2019.1638693 |
0.536 |
|
| 2019 |
Ramakrishnan S, Steck SE, Arab L, Zhang H, Bensen JT, Fontham ETH, Johnson CS, Mohler JL, Smith GJ, Su LJ, Woloszynska A. Association among plasma 1,25(OH) D, ratio of 1,25(OH) D to 25(OH)D, and prostate cancer aggressiveness. The Prostate. PMID 31077420 DOI: 10.1002/Pros.23824 |
0.475 |
|
| 2019 |
Bunch BL, Ma Y, Attwood K, Amable L, Luo W, Morrison C, Guru KA, Woloszynska-Read A, Hershberger PA, Trump DL, Johnson CS. Vitamin D enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk. Cancer Medicine. PMID 30972950 DOI: 10.1002/Cam4.2119 |
0.626 |
|
| 2019 |
Wei L, Hussein AA, Ma Y, Azabdaftari G, Ahmed Y, Wong LP, Hu Q, Luo W, Cranwell VN, Bunch BL, Kozlowski JD, Singh PK, Glenn ST, Smith G, Johnson CS, et al. Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy. The Journal of Urology. PMID 30730413 DOI: 10.1097/Ju.0000000000000481 |
0.376 |
|
| 2019 |
Dy GK, Lee K, Groman A, Cinquino A, Cedeno C, Minderman H, Hutson A, Wallace P, Johnson C, Mazorra Z, Hernandez DS, Leon K, Lage A, Crombet T. Abstract CT088: Final results of the Phase I study of nivolumab in combination with CIMAvax, an epidermal growth factor(EGF)-depleting immunotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Focus on biomarker analyses Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct088 |
0.322 |
|
| 2018 |
Fountzilas C, Javle M, Tan W, Ma Y, Fetterly G, Iyer R, Johnson C. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. PMID 30299542 DOI: 10.1002/Cncr.31676 |
0.46 |
|
| 2018 |
Steck SE, Omofuma OO, Su LJ, Maise AA, Woloszynska-Read A, Johnson CS, Zhang H, Bensen JT, Fontham ETH, Mohler JL, Arab L. Calcium, magnesium, and whole-milk intakes and high-aggressive prostate cancer in the North Carolina-Louisiana Prostate Cancer Project (PCaP). The American Journal of Clinical Nutrition. 107: 799-807. PMID 29722851 DOI: 10.1093/Ajcn/Nqy037 |
0.349 |
|
| 2018 |
Luo W, Ma Y, Cortes E, Omilian A, Bshara W, Azabdaftari G, Bunch B, Johnson C, Trump D. Abstract 4625: Tumor expression of PIM kinases in renal cell carcinoma and the association with disease progression Cancer Research. 78: 4625-4625. DOI: 10.1158/1538-7445.Am2018-4625 |
0.56 |
|
| 2017 |
Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death & Disease. 8: 3217. PMID 29242529 DOI: 10.1038/S41419-017-0024-5 |
0.353 |
|
| 2017 |
Ma Y, Luo W, Bunch BL, Pratt RN, Trump DL, Johnson CS. 1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. Oncotarget. 8: 60080-60093. PMID 28947955 DOI: 10.18632/Oncotarget.19629 |
0.603 |
|
| 2017 |
Ma Y, Luo W, Bunch BL, Pratt RN, Trump DL, Johnson CS. 1,25D3 differentially suppresses bladder cancer cell migration and invasion through the induction of miR-101-3p. Oncotarget. PMID 28778065 DOI: 10.18632/oncotarget.19629 |
0.554 |
|
| 2017 |
Mazzilli SA, Tassinari A, Xiao X, Liu G, Dhillon S, Johnson C, Reid M, Lenburg M, Spira A, Beane J. Abstract 1252: A pre-clinical model for lung cancer interception: gene expression similarities between human and mouse bronchial premalignant lesions Cancer Research. 77: 1252-1252. DOI: 10.1158/1538-7445.Am2017-1252 |
0.697 |
|
| 2017 |
Bunch BL, Trump D, Johnson CS. Abstract 1086: Vitamin D3 increases the response to cisplatin in bladder cancer through VDR and TAp73 pathway crosstalk Cancer Research. 77: 1086-1086. DOI: 10.1158/1538-7445.Am2017-1086 |
0.669 |
|
| 2016 |
Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Cortes Gomez E, Sun Y, Conroy J, Miles KM, Malathi K, ... ... Johnson CS, et al. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. PMID 27823983 DOI: 10.18632/Oncotarget.13062 |
0.34 |
|
| 2016 |
Wei L, Papanicolau-Sengos A, Liu S, Wang J, Conroy JM, Glenn ST, Brese E, Hu Q, Miles KM, Burgher B, Qin M, Head K, Omilian AR, Bshara W, Krolewski J, ... ... Johnson CS, et al. Pitfalls of improperly procured adjacent non-neoplastic tissue for somatic mutation analysis using next-generation sequencing. Bmc Medical Genomics. 9: 64. PMID 27756300 DOI: 10.1186/S12920-016-0226-1 |
0.451 |
|
| 2016 |
Luo W, Johnson CS, Trump DL. Vitamin D Signaling Modulators in Cancer Therapy. Vitamins and Hormones. 100: 433-72. PMID 26827962 DOI: 10.1016/Bs.Vh.2015.11.004 |
0.653 |
|
| 2016 |
Ma Y, Johnson CS, Trump DL. Mechanistic Insights of Vitamin D Anticancer Effects. Vitamins and Hormones. 100: 395-431. PMID 26827961 DOI: 10.1016/Bs.Vh.2015.11.003 |
0.664 |
|
| 2016 |
Trump DL, Brady WE, Aragon-Ching JB, Pili R, Levine EG, George S, Johnson CS. A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer. Journal of Clinical Oncology. 34: 5065-5065. DOI: 10.1200/Jco.2016.34.15_Suppl.5065 |
0.658 |
|
| 2016 |
Luo W, Ma Y, Chernov M, Trump DL, Johnson CS. Abstract 866: Delineation of novel CYP24A1 transcriptional regulators Endocrinology. 76: 866-866. DOI: 10.1158/1538-7445.Am2016-866 |
0.468 |
|
| 2016 |
Steck SE, Woloszynska-Read A, Antwi S, Zhang H, Arab L, Fontham ETH, Mohler J, Su LJ, Xiao F, Smith G, Trump D, Johnson C, Bensen J. Abstract 806: SNPs in vitamin D-related genes are associated with prostate cancer aggressiveness in the North Carolina-Louisiana Prostate Cancer Project (PCaP) Epidemiology. 76: 806-806. DOI: 10.1158/1538-7445.Am2016-806 |
0.6 |
|
| 2016 |
Bunch BL, Johnson CS, Trump DL. Abstract 1190: Pretreatment with 1,25 dihydroxyvitamin D3 modulates p73 levels and activity to increase pro-apoptotic effects of cisplatin in bladder cancer Cancer Research. 76: 1190-1190. DOI: 10.1158/1538-7445.Am2016-1190 |
0.647 |
|
| 2015 |
Wei L, Liu S, Conroy J, Wang J, Papanicolau-Sengos A, Glenn ST, Murakami M, Liu L, Hu Q, Conroy J, Miles KM, Nowak DE, Liu B, Qin M, Bshara W, ... ... Johnson CS, et al. Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib. Cold Spring Harbor Molecular Case Studies. 1: a000380. PMID 27148567 DOI: 10.1101/mcs.a000380 |
0.458 |
|
| 2015 |
Yao S, Haddad SA, Hu Q, Liu S, Lunetta KL, Ruiz-Narvaez EA, Hong CC, Zhu Q, Sucheston-Campbell L, David Cheng TY, Bensen JT, Johnson CS, Trump DL, Haiman CA, Olshan AF, et al. Genetic variations in vitamin D-related pathways and breast cancer risk in African American women in the AMBER Consortium. International Journal of Cancer. Journal International Du Cancer. PMID 26650177 DOI: 10.1002/Ijc.29954 |
0.59 |
|
| 2015 |
Mazzilli SA, Hershberger PA, Reid ME, Bogner PN, Atwood K, Trump DL, Johnson CS. Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model. Cancer Prevention Research (Philadelphia, Pa.). PMID 26276745 DOI: 10.1158/1940-6207.Capr-14-0403 |
0.796 |
|
| 2015 |
Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. PMID 26119935 DOI: 10.1038/Onc.2015.219 |
0.376 |
|
| 2015 |
Bothwell KD, Shaurova T, Merzianu M, Suresh A, Kuriakose MA, Johnson CS, Hershberger PA, Seshadri M. Impact of Short-term 1,25-dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 26100522 DOI: 10.1158/1940-6207.Capr-14-0454 |
0.474 |
|
| 2015 |
Steck SE, Arab L, Zhang H, Bensen JT, Fontham ET, Johnson CS, Mohler JL, Smith GJ, Su JL, Trump DL, Woloszynska-Read A. Association between Plasma 25-Hydroxyvitamin D, Ancestry and Aggressive Prostate Cancer among African Americans and European Americans in PCaP. Plos One. 10: e0125151. PMID 25919866 DOI: 10.1371/Journal.Pone.0125151 |
0.599 |
|
| 2015 |
Liu B, Conroy JM, Morrison CD, Odunsi AO, Qin M, Wei L, Trump DL, Johnson CS, Liu S, Wang J. Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives. Oncotarget. 6: 5477-89. PMID 25849937 DOI: 10.18632/Oncotarget.3491 |
0.497 |
|
| 2015 |
Ma Y, Hu Q, Luo W, Pratt RN, Glenn ST, Liu S, Trump DL, Johnson CS. 1α,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 148: 166-71. PMID 25263658 DOI: 10.1016/J.Jsbmb.2014.09.020 |
0.591 |
|
| 2015 |
Greenspan RD, Krishnan N, Morrison C, Omilian A, Bshara W, Worral A, Attwood K, Trump DL, Woloszynska-Read A, Johnson CS. Abstract LB-158: P73, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle invasive bladder cancer (MIBC) Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-158 |
0.562 |
|
| 2015 |
Bunch BL, Woloszynska-Read A, Trump DL, Johnson CS. Abstract LB-039: 1,25 dihydroxyvitamin D3 and cisplatin combination modulate p73 in bladder cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-039 |
0.612 |
|
| 2015 |
Iyer RV, Sexton S, Curtin L, Fetterly G, Maguire O, Minderman H, Toshkov I, Tennant B, Hutson A, Trump DL, Johnson C. Abstract 5144: Low dose sorafenib delays hepatocellular cancer (HCC) development in the woodchuck model of hepatitis B related HCC Cancer Research. 75: 5144-5144. DOI: 10.1158/1538-7445.Am2015-5144 |
0.516 |
|
| 2015 |
Ma Y, Luo W, Pratt R, Trump DL, Johnson CS. Abstract 5095: 1,25D3 inhibits migration and invasion through miR-101-3p in human bladder cancer cells Cancer Research. 75: 5095-5095. DOI: 10.1158/1538-7445.Am2015-5095 |
0.602 |
|
| 2015 |
Luo W, Ma Y, Baldino C, Caserta J, Ramakrishnan S, Roberto P, Johnson C, Trump D. Abstract 5056: PIM-1 kinase regulates vitamin D receptor signaling in human renal carcinoma cells Cancer Research. 75: 5056-5056. DOI: 10.1158/1538-7445.Am2015-5056 |
0.661 |
|
| 2014 |
Ma Y, Trump DL, Johnson CS. Vitamin D and miRNAs in cancer. Current Gene Therapy. 14: 269-75. PMID 25039615 DOI: 10.2174/1566523214666140612153537 |
0.605 |
|
| 2014 |
Ajibade AA, Kirk JS, Karasik E, Gillard B, Moser MT, Johnson CS, Trump DL, Foster BA. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. Plos One. 9: e89555. PMID 24586868 DOI: 10.1371/Journal.Pone.0089555 |
0.648 |
|
| 2014 |
Singh PK, Preus L, Hu Q, Yan L, Long MD, Morrison CD, Nesline M, Johnson CS, Koochekpour S, Kohli M, Liu S, Trump DL, Sucheston-Campbell LE, Campbell MJ. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget. 5: 824-40. PMID 24583788 DOI: 10.18632/Oncotarget.1776 |
0.493 |
|
| 2014 |
Yao S, Hong CC, McCann SE, Zirpoli G, Quan L, Gong Z, Johnson CS, Trump DL, Ambrosone CB. Combined effects of circulating levels of 25-hydroxyvitamin d and Th1 and th2 cytokines on breast cancer estrogen receptor status. Cancers. 6: 211-25. PMID 24473087 DOI: 10.3390/Cancers6010211 |
0.585 |
|
| 2014 |
Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, ... ... Johnson CS, et al. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: E672-81. PMID 24469795 DOI: 10.1073/Pnas.1313580111 |
0.548 |
|
| 2014 |
Lee HJ, Muindi JR, Tan W, Hu Q, Wang D, Liu S, Wilding GE, Ford LA, Sait SN, Block AW, Adjei AA, Barcos M, Griffiths EA, Thompson JE, Wang ES, ... Johnson CS, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer. 120: 521-9. PMID 24166051 DOI: 10.1002/Cncr.28368 |
0.577 |
|
| 2014 |
Steck SE, Woloszynska-Read A, Arab L, McMahon D, Bensen J, Adams JS, Fontham ETH, Mohler JL, Su LJ, Zhang H, Trump D, Johnson C. Abstract B07: Ratio of plasma 1,25(OH)2D to 25(OH)D is inversely associated with aggressive prostate cancer in African Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP) Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-B07 |
0.641 |
|
| 2014 |
Luo W, Baldino CM, Caserta J, Ma Y, Johnson C, Trump DL. Abstract 607: Targeting PIM1 kinase enhances 1,25-dihydroxyvitamin D3-mediated anti-tumor activity in bladder cancer cells Cancer Research. 74: 607-607. DOI: 10.1158/1538-7445.Am2014-607 |
0.656 |
|
| 2014 |
Pomakov A, Toshkov I, Buitrago S, Curtin L, Trump D, Johnson C, Ashton E, Tennant B, Iyer R. Abstract 4946: Developing anti-angiogenic therapies for human hepatocellular cancer (HCC)- studies of suntinib in the woodchuck model of hepatitis B related HCC Cancer Research. 74: 4946-4946. DOI: 10.1158/1538-7445.Am2014-4946 |
0.509 |
|
| 2014 |
Ciamporcero ES, Shen H, Chintala S, Ramakrishnan S, Ku SY, Miles KM, Pizzimenti S, Johnson C, Zhang J, Barrera G, Pili R. Abstract 3754: Hippo pathway effector Yes-associated protein and cisplatin resistance in transitional cell carcinoma of the bladder Cancer Research. 74: 3754-3754. DOI: 10.1158/1538-7445.Am2014-3754 |
0.408 |
|
| 2014 |
Mazzilli SA, Reid ME, Bogner PN, Attwood K, Hershberger PA, Trump DL, Johnson CS. Abstract 238: Vitamin D sufficiency slows the progression of dysplasic lesions in the NTCU mouse model of lung squamous cell carcinoma Cancer Research. 74: 238-238. DOI: 10.1158/1538-7445.Am2014-238 |
0.639 |
|
| 2014 |
Krishnan N, Woloszynska-Read A, Wang J, Liu S, Morrison C, Guru K, Smit E, Trump D, Johnson C. Abstract 2226: Loss of STAG2 in bladder cancer Cancer Research. 74: 2226-2226. DOI: 10.1158/1538-7445.Am2014-2226 |
0.565 |
|
| 2014 |
Pomakov A, Toshkov I, Buitrago S, Curtin L, Trump D, Johnson CS, Ashton E, Tennant B, Iyer R. Mo1927 Histological Changes Following Sunitinib Therapy in the Woodchuck Model of Hepatitis B Related HCC Gastroenterology. 146: S-693-S-694. DOI: 10.1016/S0016-5085(14)62517-8 |
0.445 |
|
| 2014 |
Den Haese JP, Frangou CG, Johnson CS, Trump DL, Wetzler M. 25(OH) Vitamin D3 Delays Leukemogenesis in an Acute Myeloid Leukemia Murine Model Clinical Lymphoma Myeloma and Leukemia. 14: S121-S122. DOI: 10.1016/J.Clml.2014.06.042 |
0.588 |
|
| 2013 |
Liu B, Morrison CD, Johnson CS, Trump DL, Qin M, Conroy JC, Wang J, Liu S. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget. 4: 1868-81. PMID 24240121 DOI: 10.18632/Oncotarget.1537 |
0.495 |
|
| 2013 |
Luo W, Hu Q, Wang D, Deeb KK, Ma Y, Morrison CD, Liu S, Johnson CS, Trump DL. Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue. Oncotarget. 4: 1472-83. PMID 23978847 DOI: 10.18632/Oncotarget.1269 |
0.558 |
|
| 2013 |
Godoy AS, Chung I, Montecinos VP, Buttyan R, Johnson CS, Smith GJ. Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. American Journal of Physiology. Endocrinology and Metabolism. 304: E1131-9. PMID 23548616 DOI: 10.1152/Ajpendo.00602.2012 |
0.646 |
|
| 2013 |
Muindi JR, Adjei AA, Wu ZR, Olson I, Huang H, Groman A, Tian L, Singh PK, Sucheston LE, Johnson CS, Trump DL, Fakih MG. Serum vitamin D metabolites in colorectal cancer patients receiving cholecalciferol supplementation: correlation with polymorphisms in the vitamin D genes. Hormones & Cancer. 4: 242-50. PMID 23456391 DOI: 10.1007/S12672-013-0139-9 |
0.619 |
|
| 2013 |
Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 71: 1173-82. PMID 23435876 DOI: 10.1007/S00280-013-2109-X |
0.576 |
|
| 2013 |
Ma Y, Yu WD, Hidalgo AA, Luo W, Delansorne R, Johnson CS, Trump DL. Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle (Georgetown, Tex.). 12: 743-52. PMID 23388458 DOI: 10.4161/Cc.23846 |
0.786 |
|
| 2013 |
Luo W, Yu WD, Ma Y, Chernov M, Trump DL, Johnson CS. Inhibition of protein kinase CK2 reduces Cyp24a1 expression and enhances 1,25-dihydroxyvitamin D(3) antitumor activity in human prostate cancer cells. Cancer Research. 73: 2289-97. PMID 23358686 DOI: 10.1158/0008-5472.Can-12-4119 |
0.663 |
|
| 2013 |
Luo W, Hershberger PA, Trump DL, Johnson CS. 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. The Journal of Steroid Biochemistry and Molecular Biology. 136: 252-7. PMID 23059474 DOI: 10.1016/J.Jsbmb.2012.09.031 |
0.655 |
|
| 2013 |
Ma Y, Yu WD, Su B, Seshadri M, Luo W, Trump DL, Johnson CS. Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol. Cancer. 119: 563-74. PMID 22833444 DOI: 10.1002/Cncr.27531 |
0.611 |
|
| 2013 |
Frangou CG, Den Haese J, Nowak N, Johnson CS, Trump D, Wetzler M. 25(OH) Vitamin D3 Affects Acute Myeloid Leukemia Cell Proliferation Blood. 122: 5026-5026. DOI: 10.1182/Blood.V122.21.5026.5026 |
0.645 |
|
| 2013 |
Woloszynska-Read A, Arab L, Adams J, Bensen JT, Fontham ET, Mohler JL, Su J, Tabung F, Zhang H, Trump DL, Johnson CS, Steck SE. Abstract LB-12: Plasma 25-hydroxyvitamin D levels are associated with aggressive prostate cancer among African Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP). Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-12 |
0.614 |
|
| 2013 |
Ma Y, Yu W, Hidalgo AA, Luo W, Delansorne R, Johnson CS, Trump DL. Abstract 3434: Inecalcitol, an analogue of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cancer Research. 73: 3434-3434. DOI: 10.1158/1538-7445.Am2013-3434 |
0.8 |
|
| 2013 |
Luo W, Chernov M, Ma Y, Johnson C, Trump D. Abstract 1819: Over-expression of PIM1 kinase contributes to CYP24A1 gene up-regulation in prostate cancer. Cancer Research. 73: 1819-1819. DOI: 10.1158/1538-7445.Am2013-1819 |
0.549 |
|
| 2013 |
Mazzilli SA, Reid M, Bogner P, Trump D, Johnson C. Abstract 178: Vitamin D reduces lung cancer progression the N-nitroso-tris-chloroethylurea model of mouse lung squamous cell carcinoma. Cancer Research. 73: 178-178. DOI: 10.1158/1538-7445.Am2013-178 |
0.805 |
|
| 2012 |
Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Rheumatic Diseases Clinics of North America. 38: 161-78. PMID 22525850 DOI: 10.1016/J.Rdc.2012.03.014 |
0.615 |
|
| 2012 |
Yao S, Zirpoli G, Bovbjerg DH, Jandorf L, Hong CC, Zhao H, Sucheston LE, Tang L, Roberts M, Ciupak G, Davis W, Hwang H, Johnson CS, Trump DL, McCann SE, et al. Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Research : Bcr. 14: R58. PMID 22480149 DOI: 10.1186/Bcr3162 |
0.572 |
|
| 2012 |
Yoo J, Olson I, Muindi J, Iyer R, Attwood K, Johnson C, Trump D. Serum and Bile 25(OH)D3 and 1,25(OH)2D3 Levels in Patients with Cancers Affecting the Gall Bladder and Biliary Duct: 232 The American Journal of Gastroenterology. 107. DOI: 10.14309/00000434-201210001-00232 |
0.62 |
|
| 2012 |
Ramnath N, Daignault-Newton S, Dy GK, Muindi J, Adjei A, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Johnson CS, Trump DL. A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E18118 |
0.575 |
|
| 2012 |
Luo W, Deeb KK, Liu S, Ma Y, Morrison CD, Trump DL, Johnson CS. Abstract 4280: Genome-wide expression and methylation analysis in CD31+ cells from African American and Caucasian American benign and malignant prostate tissue Cancer Research. 72: 4280-4280. DOI: 10.1158/1538-7445.Am2012-4280 |
0.565 |
|
| 2012 |
Mazzilli SA, Reid ME, Seshadri M, Bogner PN, Foster BA, Johnson CS, Trump DL. Abstract 1606: Antitumor effects of vitamin D in a carcinogen-induced mouse model of lung cancer Cancer Research. 72: 1606-1606. DOI: 10.1158/1538-7445.Am2012-1606 |
0.804 |
|
| 2012 |
Woloszynska-Read A, Wang D, Liu S, Mohler JL, Trump DL, Johnson CS. Abstract B33: Genome-wide methylation analyses reveal racial differences in blood DNA of prostate cancer patients from the North Carolina-Louisiana Prostate Cancer Project (PCaP) cohort. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B33 |
0.543 |
|
| 2011 |
Trump DL, Al-Hussaini MH, Silliman C, Jarkowski A, Johnson CS. Effect of ketoconazole/hydrocortisone (Keto/HC) on 25 (OH) vitamin D in men with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13063. PMID 28019888 DOI: 10.1200/Jco.2011.29.15_Suppl.E13063 |
0.649 |
|
| 2011 |
Al-Hussaini MH, Johnson CS, Muindi J, Chadha MK, Silliman C, Tian L, Tan W, Nesline M, Sandecki A, Kuettel MR, Mohler J, Guru K, Trump DL. Serum 25(OH) vitamin D3 response to vitamin D3 supplementation in men with prostate cancer: Results of a randomized phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e13060. PMID 28019887 DOI: 10.1200/Jco.2011.29.15_Suppl.E13060 |
0.649 |
|
| 2011 |
Woloszynska-Read A, Johnson CS, Trump DL. Vitamin D and cancer: clinical aspects. Best Practice & Research. Clinical Endocrinology & Metabolism. 25: 605-15. PMID 21872802 DOI: 10.1016/J.Beem.2011.06.006 |
0.648 |
|
| 2011 |
Hidalgo AA, Deeb KK, Pike JW, Johnson CS, Trump DL. Dexamethasone enhances 1alpha,25-dihydroxyvitamin D3 effects by increasing vitamin D receptor transcription. The Journal of Biological Chemistry. 286: 36228-37. PMID 21868377 DOI: 10.1074/Jbc.M111.244061 |
0.767 |
|
| 2011 |
Hidalgo AA, Montecinos VP, Paredes R, Godoy AS, McNerney EM, Tovar H, Pantoja D, Johnson C, Trump D, Onate SA. Biochemical characterization of nuclear receptors for vitamin D3 and glucocorticoids in prostate stroma cell microenvironment. Biochemical and Biophysical Research Communications. 412: 13-9. PMID 21763285 DOI: 10.1016/J.Bbrc.2011.06.181 |
0.767 |
|
| 2011 |
Deeb KK, Luo W, Karpf AR, Omilian AR, Bshara W, Tian L, Tangrea MA, Morrison CD, Johnson CS, Trump DL. Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate. Epigenetics : Official Journal of the Dna Methylation Society. 6: 994-1000. PMID 21725204 DOI: 10.4161/Epi.6.8.16536 |
0.568 |
|
| 2011 |
Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, Davis W, Hong CC, McCann SE, Hwang H, Kulkarni S, Edge SB, O'Connor TL, Ambrosone CB. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. Plos One. 6: e17251. PMID 21386992 DOI: 10.1371/Journal.Pone.0017251 |
0.571 |
|
| 2011 |
Chadha MK, Fakih M, Muindi J, Tian L, Mashtare T, Johnson CS, Trump D. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. The Prostate. 71: 368-72. PMID 20812224 DOI: 10.1002/Pros.21250 |
0.572 |
|
| 2011 |
Jain RK, Trump DL, Egorin MJ, Fernandez M, Johnson CS, Ramanathan RK. A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors. Investigational New Drugs. 29: 1420-5. PMID 20661623 DOI: 10.1007/S10637-010-9492-5 |
0.644 |
|
| 2011 |
Rassnick KM, Muindi JR, Johnson CS, Bailey DB, Trump DL. Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs. Cancer Chemotherapy and Pharmacology. 67: 165-71. PMID 20306264 DOI: 10.1007/S00280-010-1304-2 |
0.546 |
|
| 2011 |
Luo W, Karpf AR, Chernov MC, Johnson C, Trump D. Abstract 942: Protein kinase CK2 contributes to 1, 25-dihydroxyvitamin D3-mediated CYP24A1 gene expression in prostate cancer cells Cancer Research. 71: 942-942. DOI: 10.1158/1538-7445.Am2011-942 |
0.682 |
|
| 2011 |
Ma Y, Yu W, Kong R, Delansorne R, Trump DL, Johnson CS. Abstract 583: Inecalcitol, a 14-epi-analogue of 1,25D3, induces growth inhibition through apoptosis and cell cycle arrest in a squamous cell carcinoma model system Cancer Research. 71: 583-583. DOI: 10.1158/1538-7445.Am2011-583 |
0.659 |
|
| 2011 |
Woloszynska-Read A, Tian L, Mohler JL, Fontham ET, Bensen JT, Johnson CS, Trump DL. Abstract B81: Vitamin D and prostate cancer aggressiveness among African and European Americans in the North Carolina-Louisiana Prostate Cancer Project (PCaP) case study cohort Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-B81 |
0.651 |
|
| 2011 |
Trump DL, Johnson CS. The anti-tumor effects of vitamin D in other cancers Vitamin D. 1763-1773. DOI: 10.1016/B978-0-12-381978-9.10090-3 |
0.443 |
|
| 2011 |
Trump DL, Johnson CS. Vitamin D and cancer Vitamin D and Cancer. 1-342. DOI: 10.1007/978-1-4419-7188-3 |
0.394 |
|
| 2010 |
Ma Y, Trump DL, Johnson CS. Vitamin D in combination cancer treatment. Journal of Cancer. 1: 101-7. PMID 20842231 DOI: 10.7150/Jca.1.101 |
0.606 |
|
| 2010 |
Yu WD, Ma Y, Flynn G, Muindi JR, Kong RX, Trump DL, Johnson CS. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle (Georgetown, Tex.). 9: 3022-9. PMID 20699664 DOI: 10.4161/Cc.9.15.12381 |
0.566 |
|
| 2010 |
Malone EK, Rassnick KM, Wakshlag JJ, Russell DS, Al-Sarraf R, Ruslander DM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances mast cell tumour chemotherapy and receptor tyrosine kinase inhibitor activity in vitro and has single-agent activity against spontaneously occurring canine mast cell tumours. Veterinary and Comparative Oncology. 8: 209-20. PMID 20691028 DOI: 10.1111/J.1476-5829.2010.00223.X |
0.543 |
|
| 2010 |
Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, Johnson CS. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology. 151: 4301-12. PMID 20591973 DOI: 10.1210/En.2009-1156 |
0.569 |
|
| 2010 |
Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Research. 70: 5953-62. PMID 20587525 DOI: 10.1158/0008-5472.Can-10-0617 |
0.598 |
|
| 2010 |
Ma Y, Yu WD, Trump DL, Johnson CS. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer. 116: 3294-303. PMID 20564622 DOI: 10.1002/Cncr.25059 |
0.632 |
|
| 2010 |
Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. Endocrinology and Metabolism Clinics of North America. 39: 401-18, table of con. PMID 20511060 DOI: 10.1016/J.Ecl.2010.02.011 |
0.658 |
|
| 2010 |
Hidalgo AA, Trump DL, Johnson CS. Glucocorticoid regulation of the vitamin D receptor. The Journal of Steroid Biochemistry and Molecular Biology. 121: 372-5. PMID 20398752 DOI: 10.1016/J.Jsbmb.2010.03.081 |
0.762 |
|
| 2010 |
Johnson CS, Chung I, Trump DL. Epigenetic silencing of CYP24 in the tumor microenvironment. The Journal of Steroid Biochemistry and Molecular Biology. 121: 338-42. PMID 20304059 DOI: 10.1016/J.Jsbmb.2010.03.046 |
0.711 |
|
| 2010 |
Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer. 116: 2132-9. PMID 20166215 DOI: 10.1002/Cncr.24973 |
0.544 |
|
| 2010 |
Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer Journal (Sudbury, Mass.). 16: 1-9. PMID 20164683 DOI: 10.1097/Ppo.0B013E3181C51Ee6 |
0.676 |
|
| 2010 |
Li F, Cheng Q, Ling X, Stablewski A, Tang L, Foster BA, Johnson CS, Rustum YM, Porter CW. Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: Survivin expression overlaps with stem cell markers American Journal of Pathology. 176: 1629-1638. PMID 20133811 DOI: 10.2353/Ajpath.2010.090414 |
0.31 |
|
| 2010 |
Iyer RV, Fetterly GJ, Javle MM, Tan W, Wilding GE, Muindi J, Fakih M, Ramnath N, Johnson CS, Trump DL. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. Journal of Clinical Oncology. 28: e13031-e13031. DOI: 10.1200/Jco.2010.28.15_Suppl.E13031 |
0.525 |
|
| 2010 |
Lee HJ, Muindi J, Wei T, Wilding G, Ford LA, Sait S, Block A, Barcos M, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Johnson CS, Trump D, Wetzler M. Subnormal Vitamin D Levels Are Associated with Adverse Outcome In Newly-Diagnosed Similarly-Treated Adult Acute Myeloid Leukemia (AML) Patients. Blood. 116: 1041-1041. DOI: 10.1182/Blood.V116.21.1041.1041 |
0.595 |
|
| 2010 |
Muindi JRF, Adjei AA, Wu ZR, Tian L, Sucheston LE, Johnson CS, Trump DL, Fakih MG. Abstract 82: A comprehensive characterization of cholecalciferol supplementation induced changes in the vitamin D3metabolic pathway in metastatic colorectal cancer patients Cancer Research. 70: 82-82. DOI: 10.1158/1538-7445.Am10-82 |
0.62 |
|
| 2010 |
Ma Y, Su B, Yu W, Seshadri M, Turowski SG, Kong R, Gillard BM, Trump DL, Johnson CS. Abstract 5123: 1,25D3regulates cell-matrix and cell-cell adhesion and reduces experimental metastasis in a squamous cell carcinoma model system Cancer Research. 70: 5123-5123. DOI: 10.1158/1538-7445.Am10-5123 |
0.642 |
|
| 2010 |
Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Trump DL, Johnson CS. Abstract 4944: Regulation of vitamin D 24-hydroxylase gene expression in human prostate cancer by epigenetic mechanisms Cancer Research. 70: 4944-4944. DOI: 10.1158/1538-7445.Am10-4944 |
0.625 |
|
| 2010 |
Mazzilli SA, Reid ME, Foster BA, Johnson CS, Trump DL. Abstract 1898: The effects of 1α,25-dihydroxyvitamin D3 (calcitriol) on the tumorigenesis of lung squamous cell carcinoma Cancer Research. 70: 1898-1898. DOI: 10.1158/1538-7445.Am10-1898 |
0.778 |
|
| 2010 |
Deeb KK, Liu S, Luo W, Karpf AR, Morrison C, Johnson CS, Trump DL. Abstract 1288: Molecular features of endothelial cells isolated from benign and malignant prostatic tissues Cancer Research. 70: 1288-1288. DOI: 10.1158/1538-7445.Am10-1288 |
0.511 |
|
| 2009 |
Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, Hollis BW, Nesline MK, Tian L, Tan W, Johnson CS. Vitamin D deficiency and insufficiency among patients with prostate cancer. Bju International. 104: 909-14. PMID 19426195 DOI: 10.1111/J.1464-410X.2009.08531.X |
0.637 |
|
| 2009 |
Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 65: 33-40. PMID 19396601 DOI: 10.1007/S00280-009-1000-2 |
0.512 |
|
| 2009 |
Morrison C, Cheney R, Johnson CS, Smith G, Mohler JL. Central quadrant procurement of radical prostatectomy specimens. The Prostate. 69: 770-3. PMID 19204997 DOI: 10.1002/Pros.20925 |
0.324 |
|
| 2009 |
Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL, Johnson CS. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Research. 69: 967-75. PMID 19141646 DOI: 10.1158/0008-5472.Can-08-2307 |
0.693 |
|
| 2009 |
Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. International Journal of Colorectal Disease. 24: 219-24. PMID 18830610 DOI: 10.1007/S00384-008-0593-Y |
0.634 |
|
| 2008 |
Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS. 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Molecular Cancer Therapeutics. 7: 3047-55. PMID 18790784 DOI: 10.1158/1535-7163.Mct-08-0243 |
0.66 |
|
| 2008 |
Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. Expression and mutational analysis of MET in human solid cancers. Genes, Chromosomes & Cancer. 47: 1025-37. PMID 18709663 DOI: 10.1002/Gcc.20604 |
0.378 |
|
| 2008 |
Menezes RJ, Cheney RT, Husain A, Tretiakova M, Loewen G, Johnson CS, Jayaprakash V, Moysich KB, Salgia R, Reid ME. Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 1104-10. PMID 18483332 DOI: 10.1158/1055-9965.Epi-07-2713 |
0.422 |
|
| 2008 |
Rassnick KM, Muindi JR, Johnson CS, Balkman CE, Ramnath N, Yu WD, Engler KL, Page RL, Trump DL. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemotherapy and Pharmacology. 62: 881-91. PMID 18246349 DOI: 10.1007/S00280-008-0678-X |
0.553 |
|
| 2007 |
Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews. Cancer. 7: 684-700. PMID 17721433 DOI: 10.1038/Nrc2196 |
0.643 |
|
| 2007 |
Chung I, Yu WD, Karpf AR, Flynn G, Bernardi RJ, Modzelewski RA, Johnson CS, Trump DL. Anti-proliferative effects of calcitriol on endothelial cells derived from two different microenvironments. The Journal of Steroid Biochemistry and Molecular Biology. 103: 768-70. PMID 17368191 DOI: 10.1016/J.Jsbmb.2006.12.042 |
0.71 |
|
| 2007 |
Hidalgo AA, Paredes R, Garcia VM, Flynn G, Johnson CS, Trump DL, Onate SA. Altered VDR-mediated transcriptional activity in prostate cancer stroma. The Journal of Steroid Biochemistry and Molecular Biology. 103: 731-6. PMID 17368189 DOI: 10.1016/J.Jsbmb.2006.12.072 |
0.768 |
|
| 2007 |
Muindi JR, Nganga A, Engler KL, Coignet LJ, Johnson CS, Trump DL. CYP24 splicing variants are associated with different patterns of constitutive and calcitriol-inducible CYP24 activity in human prostate cancer cell lines. The Journal of Steroid Biochemistry and Molecular Biology. 103: 334-7. PMID 17368180 DOI: 10.1016/J.Jsbmb.2006.12.060 |
0.569 |
|
| 2007 |
Fakih MG, Trump DL, Muindi JR, Black JD, Bernardi RJ, Creaven PJ, Schwartz J, Brattain MG, Hutson A, French R, Johnson CS. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1216-23. PMID 17317832 DOI: 10.1158/1078-0432.Ccr-06-1165 |
0.506 |
|
| 2007 |
Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA. Characterization of Vitamin D insensitive prostate cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 103: 712-6. PMID 17280828 DOI: 10.1016/J.Jsbmb.2006.12.008 |
0.676 |
|
| 2007 |
Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. The Journal of Biological Chemistry. 282: 8704-14. PMID 17244627 DOI: 10.1074/Jbc.M608894200 |
0.708 |
|
| 2007 |
Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA. Antitumor effects of two less-calcemic vitamin D analogs (paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells Oncology. 70: 483-492. PMID 17237623 DOI: 10.1159/000098813 |
0.663 |
|
| 2007 |
Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemotherapy and Pharmacology. 59: 581-7. PMID 17066293 DOI: 10.1007/S00280-006-0299-1 |
0.545 |
|
| 2007 |
Muindi JR, Peng Y, Wilson JW, Johnson CS, Branch RA, Trump DL. Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients. Cancer Chemotherapy and Pharmacology. 59: 97-104. PMID 16680461 DOI: 10.1007/S00280-006-0247-0 |
0.512 |
|
| 2006 |
Flynn G, Chung I, Yu WD, Romano M, Modzelewski RA, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology. 70: 447-57. PMID 17237620 DOI: 10.1159/000098872 |
0.706 |
|
| 2006 |
Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Research. 66: 8565-73. PMID 16951169 DOI: 10.1158/0008-5472.Can-06-0905 |
0.724 |
|
| 2006 |
Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Cancer Research. 66: 8131-8. PMID 16912191 DOI: 10.1158/0008-5472.Can-06-1333 |
0.635 |
|
| 2006 |
Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Research. 26: 2551-6. PMID 16886663 |
0.63 |
|
| 2006 |
Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Research. 26: 2543-9. PMID 16886662 |
0.559 |
|
| 2006 |
Trump DL, Potter DM, Muindi J, Brufsky A, Johnson CS. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer. 106: 2136-42. PMID 16598750 DOI: 10.1002/Cncr.21890 |
0.643 |
|
| 2006 |
Trump D, Javle M, Muindi J, Pendyala L, Yu W, Ramnath N, Ross M, Fakih M, Iyer R, Johnson C. Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] in combination with gemcitabine [2’,2’ difluorodeoxycytidine] in patients with advanced malignancies Journal of Clinical Oncology. 24: 12010-12010. DOI: 10.1200/Jco.2006.24.18_Suppl.12010 |
0.509 |
|
| 2006 |
Chanan-Khan AA, Romano M, Pera P, Ersing N, Muindi J, Trump DL, Johnson C. Antiproliferative and Proapoptotic Effect of Vitamin D in Bortezomib (B) Resistant Human Myeloma Cell Line (HMCL). Blood. 108: 5074-5074. DOI: 10.1182/Blood.V108.11.5074.5074 |
0.633 |
|
| 2006 |
Conroy T, Marchal F, Blazeby JM, Matsubara T, Shintani K, Wakabayashi T, Matsumine A, Uchida A, Chung I, Romano M, Modzelewski RA, Johnson CS, Trump DL, Raderer M, Wöhrer S, et al. Contents Vol. 70, 2006 Oncology. 70: 503-506. DOI: 10.1159/000100118 |
0.583 |
|
| 2006 |
Conroy T, Marchal F, Blazeby JM, Matsubara T, Shintani K, Wakabayashi T, Matsumine A, Uchida A, Chung I, Romano M, Modzelewski RA, Johnson CS, Trump DL, Raderer M, Wöhrer S, et al. Subject Index Vol. 70, 2006 Oncology. 70: 500-502. DOI: 10.1159/000100117 |
0.581 |
|
| 2005 |
Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL. Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation. Cancer Chemotherapy and Pharmacology. 56: 492-6. PMID 15918041 DOI: 10.1007/S00280-005-1015-2 |
0.569 |
|
| 2005 |
Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, Zeng Y, Watkins SC, Johnson CS, Trump DL, Lee YJ, Xiao H, Herman-Antosiewicz A. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. The Journal of Biological Chemistry. 280: 19911-24. PMID 15764812 DOI: 10.1074/Jbc.M412443200 |
0.571 |
|
| 2004 |
Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. The Journal of Steroid Biochemistry and Molecular Biology. 89: 519-26. PMID 15225831 DOI: 10.1016/J.Jsbmb.2004.03.068 |
0.63 |
|
| 2004 |
Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ, Singh SV. Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene. 23: 5594-606. PMID 15184882 DOI: 10.1038/Sj.Onc.1207747 |
0.563 |
|
| 2004 |
Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. The Prostate. 60: 178-86. PMID 15176047 DOI: 10.1002/Pros.20045 |
0.549 |
|
| 2004 |
Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Molecular Cancer Therapeutics. 3: 567-75. PMID 15141014 |
0.495 |
|
| 2004 |
Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology. 66: 62-6. PMID 15031600 DOI: 10.1159/000076336 |
0.592 |
|
| 2003 |
Muindi JR, Wilson JW, Peng Y, Capozolli MJ, Johnson CS, Trump DL. A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients. Journal of Clinical Pharmacology. 43: 894-900. PMID 12953346 DOI: 10.1177/0091270003255925 |
0.506 |
|
| 2003 |
Srivastava SK, Xiao D, Lew KL, Hershberger P, Kokkinakis DM, Johnson CS, Trump DL, Singh SV. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis. 24: 1665-70. PMID 12896904 DOI: 10.1093/Carcin/Bgg123 |
0.584 |
|
| 2003 |
Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA. C16 ceramide accumulates following androgen ablation in LNCaP prostate cancer cells. The Prostate. 57: 66-79. PMID 12886525 DOI: 10.1002/Pros.10275 |
0.389 |
|
| 2003 |
Xiao D, Srivastava SK, Lew KL, Zeng Y, Hershberger P, Johnson CS, Trump DL, Singh SV. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis. 24: 891-7. PMID 12771033 DOI: 10.1093/Carcin/Bgg023 |
0.581 |
|
| 2002 |
Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative Effects of 1α,25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells. Endocrinology. 143: 2508-2514. PMID 28204431 DOI: 10.1210/endo.143.7.8887 |
0.361 |
|
| 2002 |
Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clinical Pharmacology and Therapeutics. 72: 648-59. PMID 12496746 DOI: 10.1067/Mcp.2002.129305 |
0.524 |
|
| 2002 |
Hershberger PA, McGuire TF, Yu WD, Zuhowski EG, Schellens JH, Egorin MJ, Trump DL, Johnson CS. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Molecular Cancer Therapeutics. 1: 821-9. PMID 12492115 |
0.591 |
|
| 2002 |
Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. Cancer Metastasis Reviews. 21: 147-58. PMID 12465754 DOI: 10.1023/A:1020836226594 |
0.654 |
|
| 2002 |
Logan TF, Jadali F, Egorin MJ, Mintun M, Sashin D, Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson C. Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemotherapy and Pharmacology. 50: 433-44. PMID 12451469 DOI: 10.1007/S00280-002-0517-4 |
0.5 |
|
| 2002 |
Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology. 60: 553-61. PMID 12385906 DOI: 10.1016/S0090-4295(02)01741-7 |
0.543 |
|
| 2002 |
Johnson CS, Hershberger PA, Bernardi RJ, Mcguire TF, Trump DL. Vitamin D receptor: a potential target for intervention. Urology. 60: 123-30; discussion 1. PMID 12231068 DOI: 10.1016/S0090-4295(02)01591-1 |
0.622 |
|
| 2002 |
Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Phase I and pharmacokinetic study of vinblastine and high-dose megestrol acetate. Cancer Chemotherapy and Pharmacology. 50: 179-85. PMID 12203099 DOI: 10.1007/S00280-002-0484-9 |
0.484 |
|
| 2002 |
Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. The Journal of Urology. 168: 756-61. PMID 12131364 DOI: 10.1016/S0022-5347(05)64740-4 |
0.57 |
|
| 2002 |
Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology. 143: 2508-14. PMID 12072382 DOI: 10.1210/Endo.143.7.8887 |
0.659 |
|
| 2001 |
McGuire TF, Trump DL, Johnson CS. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. The Journal of Biological Chemistry. 276: 26365-73. PMID 11331275 DOI: 10.1074/Jbc.M010101200 |
0.633 |
|
| 2001 |
Konety BR, Lavelle JP, Pirtskalaishvili G, Dhir R, Meyers SA, Nguyen TS, Hershberger P, Shurin MR, Johnson CS, Trump DL, Zeidel ML, Getzenberg RH. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. The Journal of Urology. 165: 253-8. PMID 11125420 DOI: 10.1097/00005392-200101000-00074 |
0.661 |
|
| 1999 |
Konety B, Pirtskalashvili G, Hershberger P, Johnson C, Getzenberg R. Vitamin D Induced Apoptosis Of Bladder Tumor Cells In Vitro The Journal of Urology. 119. DOI: 10.1097/00005392-199904010-00479 |
0.477 |
|
| 1998 |
Myers JN, Mank-Seymour A, Zitvogel L, Storkus W, Clarke M, Johnson CS, Tahara H, Lotze MT. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. The Laryngoscope. 108: 261-8. PMID 9473079 DOI: 10.1097/00005537-199802000-00019 |
0.31 |
|
| 1998 |
Yu WD, McElwain MC, Modzelewski RA, Russell DM, Smith DC, Trump DL, Johnson CS. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. Journal of the National Cancer Institute. 90: 134-41. PMID 9450573 DOI: 10.1093/Jnci/90.2.134 |
0.64 |
|
| 1997 |
Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 50: 999-1006. PMID 9426741 DOI: 10.1016/S0090-4295(97)00408-1 |
0.581 |
|
| 1997 |
Yu WD, Chang MJ, Trump DL, Johnson CS. Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity. Cancer Immunology, Immunotherapy : Cii. 44: 316-22. PMID 9298933 DOI: 10.1007/S002620050388 |
0.497 |
|
| 1997 |
McElwain MC, Modzelewski RA, Yu WD, Russell DM, Johnson CS. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. American Journal of Otolaryngology. 18: 293-8. PMID 9282244 DOI: 10.1016/S0196-0709(97)90022-3 |
0.417 |
|
| 1997 |
LAPCO P, LIGHT B, SHURIN Z, RUEGER R, JOHNSON C. In vitro inhibition of human squamous cell carcinoma colony formation by 1,25-dihydroxyvitamin D3* Otolaryngology - Head and Neck Surgery. 117: P128-P128. DOI: 10.1016/S0194-5998(97)80230-6 |
0.388 |
|
| 1997 |
MCELWAIN M, YU W, JOHNSON C. Vitamin D and glucocorticoids in a murine squamous cell carcinoma model system* Otolaryngology - Head and Neck Surgery. 117: P126-P127. DOI: 10.1016/S0194-5998(97)80226-4 |
0.434 |
|
| 1997 |
LIGHT B, YU W, JOHNSON C. Potent in vivo cell cycle and anti-tumor effects of continuous high-dose systemic vitamin D on solid tumor in a murine squamous cell carcinoma model* Otolaryngology - Head and Neck Surgery. 117: P126-P126. DOI: 10.1016/S0194-5998(97)80225-2 |
0.436 |
|
| 1996 |
McElwain MC, Lapco PE, Johnson CS. Poster 15: Enhanced Anti-Tumor Activity with the Combination of Suramin and Vitamin D in a Murine Model of Squamous Cell Carcinoma Otolaryngology–Head and Neck Surgery. 115: P82-P82. DOI: 10.1016/S0194-5998(96)80639-5 |
0.458 |
|
| 1996 |
Snyderman CH, Shantz S, Johnson C, Shapshay SM. Nutritional chemoprevention and early detection of head and neck cancer Otolaryngology-Head and Neck Surgery. 115. DOI: 10.1016/S0194-5998(96)80564-X |
0.302 |
|
| 1994 |
Evans RR, Calmels TP, Pitt BR, Brookens MA, Johnson CS, Modzelewski RA, Lazo JS. Gene therapy and endothelial cell targeting for cancer Annals of the New York Academy of Sciences. 716: 257-264. PMID 7517652 DOI: 10.1111/J.1749-6632.1994.Tb21717.X |
0.311 |
|
| 1992 |
Johnson CS. Modulation of chemotherapy antineoplastic agents with biologic agents: Enhancement of antitumor activities by interleukin-1 Current Opinion in Oncology. 4: 1108-1115. PMID 1457525 DOI: 10.1097/00001622-199212000-00016 |
0.343 |
|
| Show low-probability matches. |